Clinical trial
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
NCT00301431 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00301431 |
|---|---|
| Title | Study Evaluating the Efficacy of DVS-233 in Fibromyalgia |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design, Efficacy and Tolerability Study of 4 Fixed Doses of DVS-233 in Adult Outpatients With Fibromyalgia Syndrome |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | DVS-233 |
| Enrollment | 1,050 |
| Start date | Aug 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Mar 10, 2006 |
| Last update posted | Dec 5, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: